Q2 Earnings Estimate for Annexon Issued By HC Wainwright

Annexon, Inc. (NASDAQ:ANNX) – Equities researchers at HC Wainwright issued their Q2 2025 EPS estimates for Annexon in a report released on Tuesday, March 4th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.33) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon’s Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS and FY2029 earnings at $0.28 EPS.

Annexon (NASDAQ:ANNX) last posted its earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05).

Other research analysts have also recently issued research reports about the stock. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 target price on shares of Annexon in a research note on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Annexon currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Annexon Trading Up 3.0 %

NASDAQ:ANNX opened at $2.76 on Thursday. Annexon has a 1 year low of $2.30 and a 1 year high of $8.40. The firm has a 50 day moving average of $3.75 and a 200-day moving average of $5.34. The stock has a market capitalization of $294.20 million, a P/E ratio of -2.63 and a beta of 1.14.

Institutional Trading of Annexon

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its holdings in Annexon by 16.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company’s stock worth $10,101,000 after acquiring an additional 235,810 shares during the period. Geode Capital Management LLC grew its holdings in Annexon by 18.3% during the 3rd quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock worth $12,693,000 after acquiring an additional 331,269 shares during the period. Barclays PLC grew its holdings in Annexon by 212.0% during the 3rd quarter. Barclays PLC now owns 177,765 shares of the company’s stock worth $1,052,000 after acquiring an additional 120,789 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Annexon by 221.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 732,216 shares of the company’s stock worth $4,335,000 after acquiring an additional 504,656 shares during the period. Finally, FMR LLC grew its holdings in Annexon by 3.2% during the 3rd quarter. FMR LLC now owns 8,561,949 shares of the company’s stock worth $50,687,000 after acquiring an additional 262,229 shares during the period.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.